The ROE as of December 2024 (TTM) for NexImmune, Inc. (NEXI) is -526.91%

According to NexImmune, Inc.’s latest financial reports and current stock price. The company's current ROE is -526.91%. This represents a change of 235.32% compared to the average of -157.14% of the last 4 quarters.

NexImmune, Inc. (NEXI) Historical ROE (quarterly & annually)

How has NEXI ROE performed in the past?

The mean historical ROE of NexImmune, Inc. over the last ten years is 83.22%. The current -526.91% ROE has changed -733.13% with respect to the historical average. Over the past ten years (40 quarters), NEXI's ROE was at its highest in in the March 2023 quarter at 1.06%. The ROE was at its lowest in in the June 2024 quarter at -252.76%.

NexImmune, Inc. (NEXI) ROE by Quarter and Year

Discovering the peaks and valleys of NexImmune, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

NexImmune, Inc. (NEXI) Average ROE

How has NEXI ROE performed in the past?

The current ROE of NexImmune, Inc. (NEXI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

NexImmune, Inc. (NEXI) ROE vs. Peers

How is NEXI’s ROE compared to its peers?

NexImmune, Inc.’s ROE is greater than ZyVersa Therapeutics, Inc. (-25512.50%), greater than Palisade Bio, Inc. (-148.31%), greater than Unicycive Therapeutics, Inc. (-374.14%), less than Apexigen, Inc. (48.27%), greater than Immix Biopharma, Inc. (-102.10%), greater than TransCode Therapeutics, Inc. (-649.01%), greater than Landos Biopharma, Inc. (-73.00%), greater than Oncorus, Inc. (-82.19%), greater than Xenetic Biosciences, Inc. (-49.49%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Virios Therapeutics, Inc. (-130.35%), greater than Zura Bio Limited (-39.61%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), less than CNS Pharmaceuticals, Inc. (695.91%), greater than Sonnet BioTherapeutics Holdings, Inc. (-383.41%), greater than Mereo BioPharma Group plc (-69.11%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than PDS Biotechnology Corporation (-139.57%), greater than Inozyme Pharma, Inc. (-88.42%), greater than HOOKIPA Pharma Inc. (-49.25%),

Build a custom stock screener for NexImmune, Inc. (NEXI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NexImmune, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

NexImmune, Inc. (NEXI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like NexImmune, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.